Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
To examine the safety and immunogenicity of two formulation of liposomal adjuvant / delivery
system (VaxiSomeTM=CCS-Cholesterol [CCS/C]), combined with commercial influenza vaccine in an
elderly healthy population when given once intramuscularly (IM).